Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma To Divest Phenytoin, Promethazine Injectables To Acquire Baxter Business

This article was originally published in The Pink Sheet Daily

Executive Summary

X-Gen Pharmaceuticals will purchase the products as part of the FTC-mandated divesture. Without the transaction, Hospira would have been the only other company that sold the two drugs once Hikma acquired Baxter's entire generic injectable business.

You may also be interested in...



Hikma To Buy Bedford, Transfer Manufacturing For U.S. Generics Injectables

Ben Venue’s shuttered Ohio plant is also slated to be part of the transaction, but Hikma’s initial focus is on moving acquired assets into its production facilities, even though the Jordan-based firm expects only limited revenue from them over the next two years.

Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products

The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.

GMP Warning Letter: Teva Preempts FDA In Disclosing Problems At Jerusalem Plant

Generic giant Teva took the unusual step of disclosing the entire contents of a Jan. 31 FDA warning letter about good manufacturing process failings, as part of a Securities and Exchange Commission filing it posted online two days later.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel